Provided By GlobeNewswire
Last update: Sep 4, 2025
WARREN, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today shared asset value and potential forecast for the Company’s pipeline product, TVGN 930, for treatment of non-solid tumor malignancies stemming from Epstein-Barr Virus (EBV).
Read more at globenewswire.comNASDAQ:TVGN (9/23/2025, 11:02:23 AM)
0.8384
+0 (+0.36%)
NASDAQ:TVGNW (9/23/2025, 10:40:47 AM)
0.0528
0 (-8.17%)
Find more stocks in the Stock Screener